Efecto del ejercicio de fuerza muscular mediante bandas elásticas combinado con ejercicio aeróbico en el tratamiento de la fragilidad del paciente anciano con diabetes mellitus tipo 2 / Effect of strength exercise with elastic bands and aerobic exercise in the treatment of frailty of the elderly patient with type 2 diabetes mellitus

Objetivo: Evaluar en el paciente diabético anciano la probabilidad de mejorar la fragilidad tras realizar ejercicios de fuerza con una banda elástica y ejercicio aeróbico. Métodos: Estudio prospectivo de pacientes diabéticos mayores de 70 años, con Barthel > 80 puntos y Global Deterioration Scale-Functional Assessment Staging < 3 puntos. Se recomendaron ejercicios de fuerza con una banda elástica 3 días a la semana y caminar 30 min al día 5 días a la semana. Se revisó la adherencia a los ejercicios mediante la pregunta de Haynes-Sacket. En el momento basal y a los 6 meses se evaluaron la fragilidad según los criterios de Fried y la capacidad funcional mediante el Short Physical Performance Battery. Resultados: Un total de 44 pacientes completaron los 6 meses de seguimiento. Se produjo falta de adherencia a los ejercicios aeróbicos en el 38,6% de los casos y a los ejercicios con bandas elásticas en el 47,7%. La prevalencia de fragilidad disminuyó del 34,1% inicial al 25% a los 6 meses (p = 0,043), y el porcentaje de sujetos con una limitación funcional moderada-grave se redujo del 26,2 al 21,4% (p = 0,007). La adherencia a los ejercicios aeróbicos (p = 0,034) y la ausencia de cardiopatía isquémica coronaria (p = 0,043) predispusieron a mejorar la fragilidad. Conclusiones: Realizar durante 6 meses ejercicios de fuerza con una banda elástica y ejercicio aeróbico reduce la prevalencia de fragilidad en pacientes diabéticos ancianos. La probabilidad de mejorar la fragilidad disminuye en caso de cardiopatía isquémica coronaria y aumenta con la adherencia a los ejercicios aeróbicos

Aim: To evaluate in the elderly diabetic patient the probability of improving the frailty after performing strength exercises with an elastic band and aerobic exercise. Methods: Prospective study of diabetic patients older than 70 years, with Barthel > 80 points and Global Deterioration Scale -Functional Assessment Staging < 3 points. Strength exercises with an elastic band 3 days a week and walk 30 min a day 5 days a week were recommended. Adherence to the exercises was assessed using the Haynes-Sacket test. Frailty was assessed by the Fried criteria and functional capacity by the Short Physical Performance Battery at baseline and at 6 months. Results: 44 patients completed 6 months of follow-up. There was non-adherence to aerobic exercises in 38.6% of cases and to exercises with elastic bands in 47.7%. The prevalence of frailty decreased from an initial 34.1% to 25% at 6 months (p = 0.043) and the percentage of patients with a moderate-severe functional limitation was reduced from 26.2% to 21.4% (p = 0.007). Adherence to aerobic exercises (p = 0.034) and absence of coronary ischemic heart disease (p = 0.043) predisposed to improve frailty. Conclusions: Performing 6-month strength exercises with an elastic band and aerobic exercise reduces the prevalence of frailty in elderly diabetic patients. The probability of improving frailty decreases in case of coronary ischemic heart disease and increases with adherence to aerobic exercises

Effect of strength exercise with elastic bands and aerobic exercise in the treatment of frailty of the elderly patient with type 2 diabetes mellitus. / Efecto del ejercicio de fuerza muscular mediante bandas elásticas combinado con ejercicio aeróbico en el tratamiento de la fragilidad del paciente anciano con diabetes mellitus tipo 2.

AIM: To evaluate in the elderly diabetic patient the probability of improving the frailty after performing strength exercises with an elastic band and aerobic exercise. METHODS: Prospective study of diabetic patients older than 70 years, with Barthel >80 points and Global Deterioration Scale -Functional Assessment Staging <3 points. Strength exercises with an elastic band 3 days a week and walk 30min a day 5 days a week were recommended. Adherence to the exercises was assessed using the Haynes-Sacket test. Frailty was assessed by the Fried criteria and functional capacity by the Short Physical Performance Battery at baseline and at 6 months. RESULTS: 44 patients completed 6 months of follow-up. There was non-adherence to aerobic exercises in 38.6% of cases and to exercises with elastic bands in 47.7%. The prevalence of frailty decreased from an initial 34.1% to 25% at 6 months (p=0.043) and the percentage of patients with a moderate-severe functional limitation was reduced from 26.2% to 21.4% (p=0.007). Adherence to aerobic exercises (p=0.034) and absence of coronary ischemic heart disease (p=0.043) predisposed to improve frailty. CONCLUSIONS: Performing 6-month strength exercises with an elastic band and aerobic exercise reduces the prevalence of frailty in elderly diabetic patients. The probability of improving frailty decreases in case of coronary ischemic heart disease and increases with adherence to aerobic exercises.

Determinantes de la inercia en el tratamiento hipolipidemiante de pacientes con diabetes mellitus tipo 2 / Determinants of inertia with lipid-lowering treatment in patients with type 2 diabetes mellitus

Objetivo: Valorar el control del cLDL de pacientes con diabetes, medir la influencia en este control de la inercia con los hipolipidemiantes y explorar sus factores predictores. Métodos: Estudio de cohortes históricas de pacientes con diabetes. Se midió el porcentaje que alcanzó un cLDL dentro de objetivo. Se consideró inercia terapéutica cuando no se ajustó la dosis de los hipolipidemiantes, ni se cambió ni añadió ningún nuevo hipolipidemiante en los pacientes con cLDL inicial fuera de objetivo. Se estudiaron el cambio experimentado en el cLDL entre la primera y la última visita y la inercia con los hipolipidemiantes en función de las comorbilidades, factores de riesgo cardiovascular asociados y tratamientos utilizados. Resultados: Se incluyó a 639 pacientes (tiempo medio de seguimiento 11,1±11,2 meses). El 27,5% alcanzó un cLDL dentro de objetivo. Se produjo inercia en el 43,6% de los pacientes con un cLDL inicial fuera de objetivo. Resultaron predictores independientes de la inercia el cLDL inicial (p<0,001), la polineuropatía (p=0,014), el ajuste de los antihipertensivos (p=0,002), la adecuación de los hipolipidemiantes (p<0,001), el uso de ezetimiba (p=0,001) y la adherencia a los hipolipidemiantes (p=0,015). Conclusiones: La inercia en el tratamiento hipolipidemiante de un paciente con diabetes es menos frecuente ante valores iniciales de cLDL más altos, en los casos de polineuropatía, cuando se ajustan o cambian los antihipertensivos y cuando se detecta falta de adherencia. La prescripción inicial adecuada de estatinas y la asociación con ezetimiba disminuyen la probabilidad de caer en la inercia

Objective: To assess the control of cLDL in diabetic patients, to measure the impact on such control of inertia with lipid-lowering agents and to explore factors that allow for predicting this inertia. Methods: Study of historical cohorts of diabetic patients. The proportion of patients who achieved the target cLDL levels was estimated. Therapeutic inertia was considered when the dose of the lipid-lowering agents was not adjusted, or a lipid-lowering agent was not changed or added in patients with initial cLDL outside the target. Change in cLDL from the first to the last visit and inertia with lipid-lowering drugs were analyzed according to comorbidities, cardiovascular risk factors and treatments used. Results: The study simple consisted of 639 patients (mean follow-up time 11.1±11.2 months), of whom 27.5% achieved target cLDL levels. Inertia occurred in 43,6% of patients with initial cLDL outside the target. Independent predictors of inertia were the initial cLDL (P<0.001), polyneuropathy (P=0.014), adjustment of antihypertensive agents (P=0.002), adequacy of lipid-lowering agents (P<0.001), use of ezetimibe (P=0.001) and adherence to lipid-lowering drugs (P=0.015). Conclusions: Inertia with lipid-lowering agents in a diabetic patient is less frequent in the presence of higher cLDL values, in cases of polyneuropathy, when antihypertensive agents are adjusted or changed, and when non-adherence is detected. The adequate initial prescription of statins and the association with ezetimibe decrease the likelihood of committing inertia

Determinants of inertia with lipid-lowering treatment in patients with type 2 diabetes mellitus. / Determinantes de la inercia en el tratamiento hipolipidemiante de pacientes con diabetes mellitus tipo 2.

OBJECTIVE: To assess the control of cLDL in diabetic patients, to measure the impact on such control of inertia with lipid-lowering agents and to explore factors that allow for predicting this inertia. METHODS: Study of historical cohorts of diabetic patients. The proportion of patients who achieved the target cLDL levels was estimated. Therapeutic inertia was considered when the dose of the lipid-lowering agents was not adjusted, or a lipid-lowering agent was not changed or added in patients with initial cLDL outside the target. Change in cLDL from the first to the last visit and inertia with lipid-lowering drugs were analyzed according to comorbidities, cardiovascular risk factors and treatments used. RESULTS: The study simple consisted of 639 patients (mean follow-up time 11.1±11.2 months), of whom 27.5% achieved target cLDL levels. Inertia occurred in 43,6% of patients with initial cLDL outside the target. Independent predictors of inertia were the initial cLDL (P<0.001), polyneuropathy (P=0.014), adjustment of antihypertensive agents (P=0.002), adequacy of lipid-lowering agents (P<0.001), use of ezetimibe (P=0.001) and adherence to lipid-lowering drugs (P=0.015). CONCLUSIONS: Inertia with lipid-lowering agents in a diabetic patient is less frequent in the presence of higher cLDL values, in cases of polyneuropathy, when antihypertensive agents are adjusted or changed, and when non-adherence is detected. The adequate initial prescription of statins and the association with ezetimibe decrease the likelihood of committing inertia.

Determinantes de la adherencia a los hipoglucemiantes y a las visitas médicas en pacientes con diabetes mellitus tipo 2 / Determinants of adherence to hypoglycemic agents and medical visits in patients with type 2 diabetes mellitus

Objetivo: Valorar el control glucémico de pacientes diabéticos, medir la influencia en este control de la adherencia a los hipoglucemiantes y a las visitas médicas, y explorar factores que permitan predecir esta adherencia. Métodos: Estudio de cohortes históricas de pacientes diabéticos. Se midió el porcentaje que alcanzó una HbA1c dentro del objetivo. Se valoró la adherencia mediante la pregunta de Haynes-Sacket. Se estudiaron el cambio en la HbA1c entre la primera y la última visita, la adherencia y la asistencia a las consultas en función de las comorbilidades, los factores de riesgo cardiovascular y los tratamientos utilizados. Resultados: Se incluyeron 639 pacientes (tiempo medio de seguimiento 11,1±11,2 meses). El 66,6% alcanzó una HbA1c dentro del objetivo. El cambio en la HbA1c entre la primera y última visita se explicó en un 54,2% por la HbA1c inicial (p<0,001), en un 13% por la adherencia terapéutica (p<0,001) y en un 9,6% por la adherencia a las citas (p<0,001). La no insulinización (p=0,011) y el cese del tabaco (p=0,032) predispusieron a una mayor adherencia. La insulinización (p=0,019) y la falta de educación terapéutica (p=0,033) predispusieron a no acudir a las visitas. Conclusiones: La mejora de la HbA1c está determinada por la HbA1c inicial, la adherencia terapéutica y la asistencia a las citas. Los insulinizados tienen peor adherencia y faltan más a la consulta, los que dejan de fumar se adhieren más a los hipoglucemiantes y los que reciben educación terapéutica acuden más a la consulta (AU)

Aim: To assess glycemic control in diabetic patients, to measure the impact on such control of adherence to hypoglycemic agents and to medical visits, and to explore factors that allow for predicting adherence. Methods: Study of historical cohorts of diabetic patients. The proportion of patients who achieved the target HbA1c levels was estimated. Adherence was assessed using the Haynes-Sackett test. Change in HbA1c from the first to the last visit, adherence, and attendance to visits were analyzed according to comorbidities, cardiovascular risk factors, and treatments used. Results: The study simple consisted of 639 patients (mean follow-up time, 11.1±11.2 months), of whom 66.6% achieved target HbA1c levels. Change in HbA1c from the first to the last visit was explained in 54.2% of patients by baseline HbA1c (P<0.001), in 13% by treatment adherence (P<0.001), and in 9.6% by visit adherence (P<0.001). Non-insulinization (P=0.011) and smoking cessation (P=0.032) predisposed to greater adherence. Insulinization (P=0.019) and lack of diabetes education (P=0.033) predisposed to visit non-compliance. Conclusions: Improvement in HbA1c is determined by baseline HbA1c, treatment adherence, and attendance to visits. Patients on insulin have poorer adherence and are more likely to miss the appointments, those who stop smoking adhere more to hypoglycemic agents, and those given therapeutic education are more likely to keep the appointments (AU)

Determinants of adherence to hypoglycemic agents and medical visits in patients with type 2 diabetes mellitus. / Determinantes de la adherencia a los hipoglucemiantes y a las visitas médicas en pacientes con diabetes mellitus tipo 2.

AIM: To assess glycemic control in diabetic patients, to measure the impact on such control of adherence to hypoglycemic agents and to medical visits, and to explore factors that allow for predicting adherence. METHODS: Study of historical cohorts of diabetic patients. The proportion of patients who achieved the target HbA1c levels was estimated. Adherence was assessed using the Haynes-Sackett test. Change in HbA1c from the first to the last visit, adherence, and attendance to visits were analyzed according to comorbidities, cardiovascular risk factors, and treatments used. RESULTS: The study simple consisted of 639 patients (mean follow-up time, 11.1±11.2 months), of whom 66.6% achieved target HbA1c levels. Change in HbA1c from the first to the last visit was explained in 54.2% of patients by baseline HbA1c (P<0.001), in 13% by treatment adherence (P<0.001), and in 9.6% by visit adherence (P<0.001). Non-insulinization (P=0.011) and smoking cessation (P=0.032) predisposed to greater adherence. Insulinization (P=0.019) and lack of diabetes education (P=0.033) predisposed to visit non-compliance. CONCLUSIONS: Improvement in HbA1c is determined by baseline HbA1c, treatment adherence, and attendance to visits. Patients on insulin have poorer adherence and are more likely to miss the appointments, those who stop smoking adhere more to hypoglycemic agents, and those given therapeutic education are more likely to keep the appointments.

Efecto de las terapias incretínicas comparadas con pioglitazona y gliclazida en la esteatosis hepática no alcohólica de los pacientes diabéticos no controlados solo con metformina: estudio observacional piloto / Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study

Objetivo: Comparar el efecto de diferentes hipoglucemiantes en indicadores analíticos y ecográficos de la esteatosis hepática no alcohólica (EHNA) en pacientes con diabetes tipo 2 no controlados solo con metformina. Métodos: Estudio prospectivo de pacientes diabéticos tratados con metformina, en combinación con gliclazida, pioglitazona, sitagliptina, exenatida o liraglutida. En el momento basal y a los 6 meses la EHNA fue valorada por ecografía abdominal y se calculó el índice de fibrosis de la EHNA. Resultados: Cincuenta y ocho pacientes completaron los 6 meses de seguimiento: 15 recibieron gliclazida, 13 pioglitazona, 15 sitagliptina, 7 exenatida y 8 liraglutida. La EHNA afectó basalmente al 57,8% de los casos y su evolución ecográfica varió dependiendo de la evolución del peso (p = 0,009) y de la cintura (p = 0,012). Los porcentajes de sujetos que experimentaron una mejoría ecográfica en los diferentes grupos de tratamiento fueron: 33,3% con gliclazida, 37,5% con pioglitazona, 45,5% con sitagliptina, 80% con exenatida y 33% con liraglutida (p = 0,28). Conclusiones: La evolución ecográfica cualitativa de la EHNA en el paciente diabético tratado con metformina en combinación con otros hipoglucemiantes está vinculada a la evolución del peso y del perímetro de cintura. Son precisos ensayos clínicos de larga duración para evaluar si las terapias incretínicas se asocian a mejores resultados hepáticos que otras terapias hipoglucemiantes (AU)

Aim: To compare the effect of different hypoglycemic drugs on laboratory and ultrasonographic markers of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes not controlled on metformin alone. Methods: Prospective study of diabetic patients treated with metformin in combination with gliclazide, pioglitazone, sitagliptin, exenatide, or liraglutide. NAFLD was assessed by abdominal ultrasound and NAFLD fibrosis score was calculated at baseline and 6 months. Results: Fifty-eight patients completed 6 months of follow-up: 15 received gliclazide, 13 pioglitazone, 15 sitagliptin, 7 exenatide, and 8 liraglutide. NAFLD affected 57.8% of patients at baseline, and its ultrasonographic course varied depending on changes in weight (P = .009) and waist circumference (P = .012). The proportions of patients who experienced ultrasonographic improvement in the different treatment groups were: 33.3% with gliclazide, 37.5% with pioglitazone, 45.5% with sitagliptin, 80% with exenatide, and 33% with liraglutide (P = .28). Conclusions: Qualitative ultrasonographic NAFLD improvement in diabetic patients treated with metformin in combination with other hypoglycemic drugs is associated to change over time in weight and waist circumference. Long-term clinical trials are needed to assess whether incretin therapies result in better liver outcomes than other hypoglycemic therapies (AU)

Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study. / Efecto de las terapias incretínicas comparadas con pioglitazona y gliclazida en la esteatosis hepática no alcohólica de los pacientes diabéticos no controlados solo con metformina: estudio observacional piloto.

AIM: To compare the effect of different hypoglycemic drugs on laboratory and ultrasonographic markers of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes not controlled on metformin alone. METHODS: Prospective study of diabetic patients treated with metformin in combination with gliclazide, pioglitazone, sitagliptin, exenatide, or liraglutide. NAFLD was assessed by abdominal ultrasound and NAFLD fibrosis score was calculated at baseline and 6 months. RESULTS: Fifty-eight patients completed 6 months of follow-up: 15 received gliclazide, 13 pioglitazone, 15 sitagliptin, 7 exenatide, and 8 liraglutide. NAFLD affected 57.8% of patients at baseline, and its ultrasonographic course varied depending on changes in weight (P=.009) and waist circumference (P=.012). The proportions of patients who experienced ultrasonographic improvement in the different treatment groups were: 33.3% with gliclazide, 37.5% with pioglitazone, 45.5% with sitagliptin, 80% with exenatide, and 33% with liraglutide (P=.28). CONCLUSIONS: Qualitative ultrasonographic NAFLD improvement in diabetic patients treated with metformin in combination with other hypoglycemic drugs is associated to change over time in weight and waist circumference. Long-term clinical trials are needed to assess whether incretin therapies result in better liver outcomes than other hypoglycemic therapies.

Effect of binge eating disorder on the outcomes of laparoscopic gastric bypass in the treatment of morbid obesity.

INTRODUCTION: Previous studies about the effect of binge eating disorder (BED) on the outcomes of laparoscopic gastric bypass (LGBP) are controversial. These studies have not compared patients with and without BED according to the Bariatric Analysis and Reporting Outcome System (BAROS), which takes into account weight loss, correction of comorbidities, improvement in quality of life and complications. OBJECTIVES: To assess whether BED predicts worse outcomes after LGBP, according to BAROS parameters. METHODS: We carried out a cohort study which included 45 morbidly obese patients operated with LGBP. Patients with preoperative BED were identified by Questionnaire on Eating and Weight Patterns-Revised and results were evaluated by BAROS system. RESULTS: Prevalence of BED was 21.4%. Median postoperative follow-up was 12 months. BED patients experienced after LGBP lower rates of resolution of hypertension (42.9% vs. 92.9%; p = 0.025) and were complicated by stenosis of the gastrojejunal anastomosis more frequently (70% vs. 17.1%; p = 0.003) than patients without binge eating. No differences in BAROS score, percentage of excess weight loss and quality of life were found. CONCLUSIONS: BED patients experienced after LGBP lower rates of resolution of hypertension and higher rates of anastomotic stenosis. BAROS score, weight loss and quality of life are comparable to that of patients without BED.

Introducción: Los estudios previos sobre el efecto del trastorno por atracón en los resultados del tratamiento de la obesidad mediante bypass gástrico por vía laparoscópica (LGBP) son controvertidos. Faltan trabajos que comparen a pacientes con y sin trastorno por atracón según el sistema BAROS, que incluye: el porcentaje de sobrepeso perdido, la evolución de las comorbilidades, la calidad de vida y las complicaciones. Objetivo: Estudiar si el trastorno por atracón predispone a peores resultados tras el LGBP en los términos que definen el sistema BAROS. Métodos: En un estudio de cohortes con 45 obesos mórbidos intervenidos mediante LGBP, se identificó a los pacientes con trastorno por atracón prequirúrgico mediante el Questionnaire on Eating and Weight Patterns- Revised y se valoró sus resultados según los parámetros incluidos en el sistema BAROS. Resultados: El 21,4% de los pacientes presentaban trastorno por atracón. La mediana de seguimiento postoperatorio fue 12 meses. Los pacientes con trastorno por atracón presentaron menor tasa de resolución de la hipertensión arterial (42,9% frente a 92,9%; p = 0,025) y mayor frecuencia de estenosis de la anastomosis gastroyeyunal (70% frente al 17,1%; p = 0,003) que los pacientes sin trastorno por atracón. No se encontraron diferencias entre los grupos con y sin trastorno por atracón respecto al porcentaje de sobrepeso perdido, calidad de vida y puntuación global BAROS. Conclusiones: Los obesos con trastorno por atracón presentan tras el LGBP menores tasas de resolución de la hipertensión arterial y se complican más frecuentemente con una estenosis de la anastomosis gastroyeyunal. La valoración BAROS, la pérdida de peso y la calidad de vida son equiparables a la de los pacientes sin trastornopor atracón.

Effect of binge eating disorder on the outcomes of laparoscopic gastricbypass in the treatment of morbid obesity / Efecto del trastorno por atracón en los resultados del bypass gástrico laparóscopico en el tratamiento de la obesidad mórbida

INTRODUCTION: Previous studies about the effect of binge eating disorder (BED) on the outcomes of laparoscopic gastric bypass (LGBP) are controversial. These studies have not compared patients with and without BED according to the Bariatric Analysis and Reporting Outcome System (BAROS), which takes into account weight loss, correction of comorbidities, improvement in quality of life and complications. OBJECTIVES: To assess whether BED predicts worse outcomes after LGBP, according to BAROS parameters. METHODS: We carried out a cohort study which included 45 morbidly obese patients operated with LGBP. Patients with preoperative BED were identified by Questionnaire on Eating and Weight Patterns-Revised and results were evaluated by BAROS system. RESULTS: Prevalence of BED was 21.4%. Median postoperative follow-up was 12 months. BED patients experienced after LGBP lower rates of resolution of hypertension (42.9% vs. 92.9%; p = 0.025) and were complicated by stenosis of the gastrojejunal anastomosis more frequently (70% vs. 17.1%; p = 0.003) than patients without binge eating. No differences in BAROS score, percentage of excess weight loss and quality of life were found. CONCLUSIONS:BED patients experienced after LGBP lower rates of resolution of hypertension and higher rates of anastomotic stenosis. BAROS score, weight loss and quality of life are comparable to that of patients without BED (AU)

Introducción: Los estudios previos sobre el efecto del trastorno por atracón en los resultados del tratamiento de la obesidad mediante bypass gástrico por vía laparoscópica (LGBP) son controvertidos. Faltan trabajos que comparen a pacientes con y sin trastorno por atracón según el sistema BAROS, que incluye: el porcentaje de sobrepeso perdido, la evolución de las comorbilidades, la calidad de vida y las complicaciones. Objetivo: Estudiar si el trastorno por atracón predispone a peores resultados tras el LGBP en los términos que definen el sistema BAROS. Métodos: En un estudio de cohortes con 45 obesos mórbidos intervenidos mediante LGBP, se identificó a los pacientes con trastorno por atracón prequirúrgico mediante el Questionnaire on Eating and Weight Patterns- Revised y se valoró sus resultados según los parámetros incluidos en el sistema BAROS. Resultados: El 21,4% de los pacientes presentaban trastorno por atracón. La mediana de seguimiento postoperatorio fue 12 meses. Los pacientes con trastorno por atracón presentaron menor tasa de resolución de la hipertensión arterial (42,9% frente a 92,9%; p = 0,025) y mayor frecuencia de estenosis de la anastomosis gastroyeyunal (70% frente al 17,1%; p = 0,003) que los pacientes sin trastorno por atracón. No se encontraron diferencias entre los grupos con y sin trastorno por atracón respecto al porcentaje de sobrepeso perdido, calidad de vida y puntuación global BAROS. Conclusiones: Los obesos con trastorno por atracón presentan tras el LGBP menores tasas de resolución de la hipertensión arterial y se complican más frecuentemente con una estenosis de la anastomosis gastroyeyunal. La valoración BAROS, la pérdida de peso y la calidad de vida son equiparables a la de los pacientes sin trastornopor atracón (AU)